Positron Emission Tomography (PET) is a test already frequently used for imaging in Oncology. By using a membrane receptor ligand called “Prostate Specific Membrane Antigen” (PSMA), PET imaging is the most precise test allowing the detection of prostate cancer and its spread. It is the optimal test for initial staging of high risk prostate cancer and in identification of the sites of disease in biochemical recurrence, allowing personalized treatment. This project is studying the differences in management in 142 patients with prostate cancer who have a PSMA PET/CT by evaluating the differences between the planned management prior to the PSMA PET/CT the actual management following the test.